ReviewCancer drug resistance (Alhambra, Calif.)2020

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.

Reema Wahdan-Alaswad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.